Biopharmas in Asia-Pacific raising money in public or private financings: Aptose, Hanmi, Jyong, Polypid, Recce.

Med-tech firms raising money in public or private financings, including: Archimedes Vascular.

Biopharmas raising money in public or private financings, including: Aptose, Bausch + Lomb, Hanmi, Jyong, Moleculin, Paradigm, Pioneer, Quince.

Med-tech firms raising money in public or private financings, including: Commure, Droplet IV, Genomes.io, Moss Genomics, Seastar Medical.

Keymed Biosciences Co. Ltd. has raised HK$982 million (US$125 million) in a placement on the Hong Kong Stock Exchange (HKEX:2162) to commercialize its IL-4Rα monoclonal antibody CM-310 branded as Stapokibart, and to advance its larger pipeline.

Biopharmas raising money in public or private financings, including: Actio, Acurx, Biomea Fusion, Cantargia, Cynaptec, Lobe Sciences, Nanocell, Polyactiva.

Med-tech firms raising money in public or private financings, including: Caris Life Sciences, Deski, Glytec, Materna Medical, Precisedx.

Jyong Biotech Ltd. raised $20 million from its Nasdaq debut June 17 to advance a pipeline of botanical drugs targeting male urinary disorders. The New Taipei City, Taiwan-headquartered company’s shares began trading under the ticker MENS, and closed at $10.11 apiece at the bell, up 34.80% from its listing price of $7.50 per share. Shares had kicked up to $15 at opening, reaching double its offering price.